Neutrophil Activation and NETosis: Pathway, Function and Assays

The neutrophil is the most heavily armed short-lived cell in the body. It leaves the marrow with its weapons already made — granules preloaded with elastase, myeloperoxidase and defensins — and spends most of its life doing nothing. Activation is therefore not about building an effector programme but about releasing one, in stages, against a gradient. Get the staging wrong and the machinery that sterilises an abscess produces acute lung injury, immunothrombosis or ANCA vasculitis. This map follows the sequence from priming to PAD4-driven NETosis and the signals that switch it off.

Priming: raising the ceiling before anything fires

Neutrophil output and lifespan are set by two colony-stimulating factors. G-CSF on G-CSFR drives granulopoiesis and marrow release, while GM-CSF through the shared βc receptor extends survival by sustaining Mcl-1, the one anti-apoptotic protein with a half-life short enough to match the cell it protects. Upstream sits IL-17A, which induces G-CSF, CXCL1 and CXCL2 from stroma and epithelium — which is why IL-17 blockade gives a neutrophil-poor tissue phenotype without ever touching the neutrophil.

Priming proper comes from inflammatory receptors. TNF via TNFR1, IL-1β via IL-1R1 and LPS presented by CD14 to TLR4–MD-2 converge on MyD88/IRAK and TAK1, branching into NF-κB p65 and p38 MAPK with its substrate MK2. None of these receptors triggers the oxidative burst on its own. TREM-1 likewise initiates nothing by itself; it amplifies TLR and FPR output several-fold, which is what makes it an attractive way to damp sepsis without abolishing pathogen sensing altogether.

The non-obvious point is that priming is mostly a trafficking event, not a transcriptional one. A neutrophil circulating for hours has little time to make protein, so it primes by fusing secretory vesicles with the plasma membrane, raising surface density of Mac-1 (CD11b), CD14, FPR1 and TREM-1 while ADAM17 sheds L-selectin from the same surface. The cell has not been activated; it has been rearmed. CD11b up with CD62L down is the standard flow readout for that state.

Recruitment: the adhesion cascade and the chemoattractant hierarchy

Endothelial injury releases vWF and mobilises P-selectin to the luminal surface, where it captures PSGL-1 and starts rolling. Rolling cells sample endothelium-bound CXCL8/IL-8, CXCL1 and CXCL2 via CXCR1 and CXCR2, triggering inside-out activation of the β₂ integrins: LFA-1 (CD11a) and Mac-1, both paired with CD18, bind ICAM-1 and arrest the cell, after which CD44 assists transmigration. Losing CD18 causes LAD-I — neutrophilia in blood, none in tissue — the cleanest proof that arrest, not production, is rate-limiting.

In tissue the cell must choose between competing gradients, and it does so hierarchically. End-target signals — bacterial fMLP through FPR1 and C5a through C5aR1 (CD88) — override intermediary ones such as CXCL8, LTB₄ through BLT1 and PAF through PAFR. All are Gαi-coupled: released Gβγ recruits PI3Kγ to make PIP₃ at the front, restrained at the rear by PTEN, while PLCβ2 generates IP₃ and DAG. STIM1 senses store depletion and ORAI1 refills; this sustained Ca²⁺ signal is what licenses degranulation.

Polarity is executed by two opposing GTPase modules. Vav1, P-Rex1 and DOCK2 load Rac1, Rac2 and Cdc42 at the front, where WASP and WAVE2 nucleate branched actin through Arp2/3 to build the lamellipodium, with cofilin severing filaments to keep barbed ends available. At the rear, RhoA and ROCK1 drive myosin-IIA contraction of the uropod. Ageing neutrophils upregulate CXCR4 and follow CXCL12 back to the marrow for clearance — a homing step, not a chemotactic one.

The respiratory burst: NOX2 has to be built first

NOX2 (gp91phox) and p22phox sit together as flavocytochrome b558 in the membranes of secretory vesicles and specific granules, catalytically inert until the cytosolic subunits arrive. Phosphorylation of p47phox by PKCδ, p38 and Akt opens its autoinhibited conformation, letting it carry p67phox and p40phox to the membrane, where GTP-loaded Rac2 docks separately to complete the enzyme. Chronic granulomatous disease is the proof: mutation in any one of the five abolishes superoxide and gives the same syndrome.

The chemistry that follows is deliberately indiscriminate. NOX2 makes superoxide (O₂•⁻), SOD dismutates it to H₂O₂, and myeloperoxidase uses H₂O₂ plus chloride to generate hypochlorous acid. HOCl is the most bactericidal product the cell makes and the least selective, so the location of the burst matters more than its size: sealed in a phagosome it sterilises, released outside it oxidises host protein and lipid. Plasma or lavage MPO therefore reports where degranulation happened, not how much.

Degranulation: four compartments with four thresholds

Granules empty in reverse order of formation, each class needing a higher calcium concentration than the last. Secretory vesicles go first, delivering the CD11b, CD14 and FPR1 reservoir described above. Gelatinase granules follow with MMP-9 and NGAL; specific granules release lactoferrin, LL-37 and more NOX2; azurophilic granules discharge last and only under strong stimulation, carrying MPO, elastase, proteinase 3, cathepsin G, MMP-8 and α-defensins. Rab27a licenses fusion for all four tiers at once.

Granule contents are the pathway's clinical face. S100A8/A9 acts as an alarmin on TLR4 and feeds the priming loop back on itself; arginase-1 depletes local arginine and suppresses T cells, which is how neutrophils act immunosuppressively in tumours. PR3 and elastase are the two ANCA autoantigens: in vasculitis the cargo becomes the target. Upstream, GPI-anchored FcγRIIIb and ITAM receptors signal through Hck/Fgr/Lyn, Syk, Btk and ERK1/2 to set how much is released.

NETosis and the resolution programme

Classical suicidal NETosis is slow — two to four hours — and NOX2-dependent. Oxidants let elastase and MPO escape azurophilic granules into the nucleus, where elastase clips histones and PAD4, a calcium-dependent deiminase, converts arginine residues on histone H3 to citrulline. The resulting citH3 loses positive charge, DNA–histone binding weakens, and chromatin decondenses until the nuclear envelope ruptures. Cytoplasmic and granule contents mix with the decondensed DNA before the plasma membrane gives way, releasing NETs studded with MPO and elastase.

A second route is much faster. Cytosolic LPS engages caspase-4/11, which cleaves gasdermin D; the resulting pores permeabilise granule and nuclear membranes and produce NETs without NOX2. A vital variant expels chromatin by vesicle transport and leaves the neutrophil alive and still crawling. The distinction is not academic: NOX2-deficient cells fail the first route entirely but keep the second, so a NET-negative result in one assay is not evidence that release is globally blocked, and NETs decorated with tissue factor underpin immunothrombosis either way.

Resolution runs through the same receptor family that started the response. Annexin A1 acting on FPR2/ALX — a receptor that also binds pro-inflammatory peptides — halts recruitment and promotes clearance, making this a ligand-dependent switch rather than a separate pathway. Mcl-1 decays, caspase-3 is activated, phosphatidylserine is exposed, and macrophage efferocytosis induces TGF-β and IL-10. Failure at this final step, not excess recruitment, is what turns acute neutrophilic inflammation chronic — so efferocytic index deserves measuring alongside infiltrate counts.

Key targets and matching reagents

Studying neutrophil activation and NETosis in vivo

Because so much of this pathway is surface receptors and secreted cytokines, it is unusually tractable with functional-grade antibodies. Experiments fall into three groups.

1. Depleting and tracking the neutrophil compartment

Anti-Ly-6G is the specific depleting reagent; anti-Gr-1 (RB6-8C5) recognises Ly-6G and Ly-6C and so removes inflammatory monocytes as well, the commonest confound in this field. Run anti-Ly-6C (HK1.4) alongside to establish which compartment a phenotype belongs to, and block with anti-CD16/CD32 (2.4G2) before staining so FcγR capture does not masquerade as specific binding. The full In Vivo range is supplied low endotoxin.

2. Interrupting recruitment and adhesion

Anti-ICAM-1 (BE29G1), anti-CD18 (M18/2), anti-CD11b and anti-CD11a dissect the arrest step, and comparing them shows whether a phenotype depends on LFA-1, Mac-1 or both. Anti-CD62L addresses tethering, anti-CD44 (IM7) transmigration, anti-CXCR4 (12G5) the marrow return route. Since blockade and depletion both lower tissue counts, pairing them is the only reliable way to separate a recruitment defect from a numbers defect.

3. Neutralising priming signals and quantifying output

Anti-TNF, anti-TNFR1 (55R-170), anti-IL-1β, anti-IL-1R1, anti-IL-17A (17F3), anti-GM-CSF and anti-TREM-1 (TREM-26) each remove one input to the primed state. Convert the result into numbers with ELISA readouts for MPO, elastase, PR3, NGAL, S100A8/A9, MMP-9 and LTB₄, adding PAD4 and a citrulline antibody when NETs are the endpoint.

Featured products for this pathway

Frequently asked questions

For research use only. Not for use in diagnostic or therapeutic procedures.